Treatments aimed at angiogenesis (new blood vessel growth) in the eye are called “antiangiogenic therapies”. They are also called “anti-VEGF therapies” because the treatments aim at a protein called VEGF found to be a primary cause of blood vessel growth in the eye. Anti-VEGF therapies can slow the progression of AMD and in some cases improve vision. The treatments are only beneficial, however, when they are used before scar tissue and irreversible vision loss develops.